Macrogenics, Inc., was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development, manufacture and commercialization of innovative antibody therapies for the treatment of cancer. The company develops product candidates through its proprietary suite of next-generation antibody technology platforms and believes this platform can improve the performance of monoclonal antibodies and antibody-derived molecules. With knowledge of disease biology and immune-mediated mechanisms, the company has identified these product candidates that may address the challenges posed by specific diseases that cannot be treated by existing therapies. The company not only develops differentiated molecules for new cancer targets, but also improves the efficacy of marketed drugs.